Persona BBB and Consumer-Complaint Trends: Is Persona Legit?

What Is Persona Nutrition and How Does the Business Model Work?

Persona Nutrition is a direct-to-consumer personalized supplement subscription service founded in 2017 and acquired by Nestlé Health Science in 2019. Customers complete an online health questionnaire, and the algorithm recommends a daily vitamin-and-supplement pack mailed monthly. Packs typically cost between $30 and $60 per month.

The subscription model is central to how the company generates revenue. Customers agree to recurring billing at checkout. That structure creates the most common friction point between Persona and its customers: cancellations that are harder to execute than sign-ups.

What Persona Sells

Persona sells dietary supplements, not prescription drugs or compounded medications. Products include omega-3 fatty acids, magnesium, B vitamins, probiotics, and adaptogens such as ashwagandha. Because these are regulated as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994, the FDA does not approve them for efficacy before sale. The FDA's role is largely post-market: the agency may act on adulteration, misbranding, or unsafe ingredients after a product reaches consumers.

Nestlé Health Science Ownership

The 2019 acquisition by Nestlé Health Science gave Persona significantly more distribution infrastructure. It also means complaints against Persona may involve a corporate parent with more legal resources. Consumer advocates recommend checking both the Persona-specific BBB profile and the parent company's standing when assessing complaint resolution history.

Persona's BBB Rating and Accreditation Status

As of mid-2025, Persona Nutrition holds an A+ letter grade from the Better Business Bureau and carries full BBB accreditation. A high letter grade reflects the BBB's assessment of complaint volume relative to company size, time in business, response to complaints, and absence of government actions, not an independent audit of product quality.

How the BBB Grades Work

The BBB assigns letter grades from A+ down to F using a proprietary point system that weights 13 factors, including failure to respond to complaints and government actions against the business. An A+ grade does not mean no complaints exist. Persona has received hundreds of complaints over the past three years, most of them resolved (closed by the BBB) but many marked as resolved only because the company responded, not necessarily because the customer was satisfied.

Consumers should read complaint texts directly at bbb.org rather than relying solely on the letter grade. A pattern of identical complaint language across dozens of filings tells a different story than a raw grade.

Complaint Volume and Trajectory

BBB data available through mid-2025 shows that Persona's complaint filings rose noticeably between 2021 and 2023, then moderated slightly in 2024 following updates to Persona's cancellation flow. The most common complaint categories, in rough order of frequency, are:

• Difficulty canceling a subscription online without phone contact
• Charges appearing after a customer believed the account was canceled
• Delays between cancellation and the last shipment, leading to disputes
• Supplement quality complaints (rare but present)
• Refund denial on opened packages

How Persona Responds to BBB Complaints

Persona's pattern of BBB responses generally involves a direct contact offer and a partial or full refund. The company's written responses on the BBB portal are professional. Still, several complainants filed follow-up rebuttals stating the offered resolution did not match what was delivered. A rebuttal rate above 15 percent of closed complaints is worth watching, because it suggests a gap between promised and actual resolution.

FDA Regulatory Standing: What DSHEA Means for Consumers

Persona's products fall under the Dietary Supplement Health and Education Act of 1994, which the FDA describes as placing "the burden of proving a dietary supplement is unsafe ... On the agency rather than the manufacturer." This is a meaningful consumer-protection gap compared to pharmaceutical oversight.

The FDA's Center for Food Safety and Applied Nutrition (CFSAN) monitors dietary supplement safety through the MedWatch adverse-event reporting system and issues warning letters when companies make illegal drug claims. Persona's public record on the FDA Warning Letter database shows no warning letters issued to the brand as of the most recent search in July 2025, though the absence of a warning letter does not confirm safety or efficacy of any specific product.

DSHEA and Health Claim Restrictions

Under DSHEA and FTC regulations, supplement companies may make "structure/function" claims (for example, "supports immune health") but may not claim to diagnose, cure, treat, or prevent any disease. Persona's product pages use language consistent with structure/function claims. Consumers should be cautious of any third-party social-media promotion associated with Persona that uses stronger disease-treatment language, because that language would not have been cleared by the company's legal team and could misrepresent what the products actually do.

The FTC's 2023 Health Products Compliance Guidance updated its framework for what constitutes "competent and reliable scientific evidence" for supplement claims. Persona, like all supplement brands, must meet that standard for any claim made in advertising.

Current Good Manufacturing Practices

The FDA requires dietary supplement manufacturers to follow Current Good Manufacturing Practices (cGMP) codified at 21 CFR Part 111. These rules govern identity testing of raw ingredients, contamination controls, and label accuracy. Persona states on its website that its manufacturing partners follow cGMP. Consumers who want independent verification can look for NSF International or USP certification on specific product labels, third-party marks that involve actual lot-by-lot testing rather than self-attestation.

LegitScript and Third-Party Verification

LegitScript is a compliance certification service used widely by Google, Meta, and payment processors to vet health and pharmacy companies before allowing them to advertise. LegitScript classifies entities as Certified, Not Certified (Rogue), or Not Applicable.

Because Persona sells dietary supplements rather than prescription drugs, it does not fall under LegitScript's pharmacy certification pathway. LegitScript's pharmacy certification applies to online pharmacies dispensing controlled or Rx medications. Persona is therefore classified as "not applicable" to the pharmacy standard rather than "rogue," and the absence of a LegitScript pharmacy badge should not be read as a red flag for a supplement company.

For consumers wanting analogous verification of a supplement company, NSF International's Certified for Sport program and the USP Verified Mark are the more relevant benchmarks. Neither certification covers Persona's full product line as of this writing.

Subscription-Trap Complaints and ROSCA Compliance

The Restore Online Shoppers' Confidence Act (ROSCA), enforced by the FTC, requires that online subscription services clearly disclose recurring charges before billing, obtain express consent, and provide a simple mechanism to cancel. The FTC has brought enforcement actions under ROSCA against supplement and health-product subscription companies.

A review of Persona's complaint pattern against ROSCA's three core requirements produces the following assessment:

Disclosure of recurring charges. Persona's checkout page includes recurring-charge language. Complaints suggest the disclosure is present but visually de-emphasized relative to promotional pricing, which the FTC's "negative option" rule updates (proposed in 2023, finalized in 2024) specifically target.

Express informed consent. The checkout flow requires a checkbox. This satisfies the literal consent requirement, but several complainants report checking the box without understanding the full annual cost, suggesting the disclosure was not sufficiently salient.

Simple cancellation mechanism. This is where the bulk of Persona complaints concentrate. Between 2021 and early 2024, cancellation required a phone call or chat, not a self-service online option. Persona updated its cancellation flow in 2024 to include an online option. Post-update complaint volume on this specific issue has declined, though it has not disappeared.

The FTC's 2024 "click-to-cancel" rule, which took effect in May 2025, requires that cancellation be as easy as sign-up. Persona's current flow, with an online cancellation option, is directionally compliant, though the FTC's enforcement posture on residual friction (multi-step confirmation screens, upsell interstitials before cancellation) is still developing.

State Attorney-General Actions

No state attorney-general enforcement action specifically naming Persona Nutrition has appeared in public databases as of July 2025. Consumers in states with strong consumer-protection statutes (California, New York, Illinois, and Florida, among others) have additional remedies under state law beyond federal ROSCA if they believe a company has engaged in deceptive billing.

Consumer Complaints Beyond Billing: Product Quality and Health Claims

Billing complaints dominate the Persona complaint record, but a smaller subset raises product-quality and health-claim concerns. These warrant separate analysis.

Allergen and Ingredient Accuracy

Several BBB complaints allege that Persona's product recommendations included ingredients to which customers had disclosed sensitivities in the intake questionnaire. Cross-referencing disclosed allergies with recommended products is a core function Persona advertises. When that function fails, it is both a customer-service failure and potentially a safety issue depending on the severity of the sensitivity.

The FDA's cGMP rules require label accuracy, but they do not specifically govern algorithmic recommendation systems. Consumers with documented food allergies should independently verify every ingredient in their recommended pack against the actual supplement-facts panel before consuming, rather than relying solely on the algorithm's output.

Efficacy Claims in Third-Party Reviews

Paid or incentivized review practices are regulated by the FTC's Endorsement Guides, updated in 2023 to require clearer disclosure of material connections between reviewers and brands. Several influencer posts promoting Persona visible on social platforms as of early 2025 did not carry clear "#ad" or "#sponsored" disclosures. Consumers should treat undisclosed influencer reviews of any supplement brand with skepticism regardless of the platform.

Supplement-Drug Interactions

Persona's intake questionnaire asks about medications. The company states that a clinical team reviews recommendations for customers on prescription medications. No peer-reviewed publication has independently audited the accuracy of Persona's medication-interaction screening as of this writing. Consumers taking anticoagulants, thyroid medications, or antidepressants should discuss any supplement addition with their prescribing physician or a registered pharmacist before starting, regardless of what an algorithm recommends.

How Persona Compares to the Broader Personalized-Supplement Market

Persona competes with Care/of (acquired by Bayer in 2020), Ritual, Rootine, and Thorne's subscription offering. Complaint patterns across this category share a common thread: subscription-cancellation friction is the number-one consumer grievance for every major personalized-supplement brand reviewed by the BBB, not product safety.

The FDA does not publish brand-level adverse-event data in a consumer-facing format. The agency's CFSAN Adverse Event Reporting System (CAERS) database is available at the FDA website but requires FOIA requests or database downloads for granular brand-level analysis. A 2022 JAMA Network Open study examining CAERS data from 2004 to 2020 found that weight-loss and sexual-enhancement supplements accounted for the largest proportion of serious adverse events, not the multivitamin and general-wellness category where Persona primarily operates.

The American Medical Association's published position, articulated in Policy H-480.958, states that dietary supplements should be subject to the same rigorous pre-market approval standards applied to conventional drugs. That policy has not become law, but it reflects the clinical community's concern about the current oversight gap under DSHEA that affects Persona and every competitor in this space.

Practical Consumer Guidance Before Subscribing to Persona

Before entering a Persona subscription, consumers benefit from taking several concrete steps.

Verify the Current Cancellation Process

Contact Persona's customer service before subscribing and ask for written confirmation of the exact cancellation steps. Save that communication. As of mid-2025, Persona's online cancellation option is accessible from the account dashboard under "Subscription." Confirm this pathway still exists at the time you subscribe, because platform changes can remove it.

Read the Subscription Terms on the Order Page

Do not rely on marketing emails or landing pages for the terms. The legally binding disclosure is on the checkout page. Note the billing cycle, the cutoff date by which you must cancel to avoid the next shipment, and the return policy for opened versus unopened products.

Cross-Check Every Ingredient

Use the NIH Office of Dietary Supplements' Dietary Supplement Label Database, available at the NIH website, to verify that each ingredient in your recommended pack is accurately labeled and that the dose falls within the range supported by available evidence. The NIH ODS also publishes individual ingredient fact sheets with evidence summaries.

Report Problems Correctly

If a billing dispute arises, file with both the BBB and your state attorney-general's consumer-protection division. For ingredient safety concerns, submit a MedWatch report to the FDA. These reports feed regulatory databases and may contribute to future enforcement actions even if they do not produce immediate individual relief.

The Bottom Line on Persona's Legitimacy

Persona is a legally operating, BBB-accredited supplement subscription service with no FDA warning letters and no state enforcement actions on record as of mid-2025. Those facts matter. The brand is not operating outside the law.

The legitimate concerns center on three areas that are well-documented in the complaint record. Subscription billing friction remains the primary consumer-protection risk. The DSHEA regulatory gap means product efficacy is self-claimed rather than FDA-verified. And the algorithmic supplement recommendation system has not been independently validated in a peer-reviewed clinical trial.

Consumers who want personalized supplement guidance backed by clinical evidence should discuss supplementation with a board-certified physician or registered dietitian who can order serum micronutrient testing (such as a comprehensive metabolic panel, a 25-hydroxyvitamin D level, and a serum ferritin) before recommending any supplement. A serum 25-hydroxyvitamin D <20 ng/mL confirmed by Quest or LabCorp testing is a clinically documented indication for supplementation. An algorithm-derived recommendation without that baseline is a commercial decision, not a medical one.